What Метацин Treats — Main Uses and Benefits

Метацин (Indomethacin) is used in situations involving certain distressing symptoms, particularly those related to inflammatory or irritative states. It may be part of symptomatic management across domains where additional symptomatic support is needed. This medication is commonly used to relieve symptoms related to physical discomfort and inflammatory or irritative states.

It is commonly used to help with symptom clusters that may become intense or disruptive, especially pain, tenderness, and swelling. It is applied in conditions presenting with systemic or localized discomfort, such as rheumatoid arthritis, osteoarthritis, acute gouty arthritis, and certain musculoskeletal injuries. This supportive role contributes to improved comfort when symptoms are more noticeable, and may offer symptomatic relief during flare-ups and acute episodes.

The medicine also plays a role in managing symptoms related to systemic imbalance, including fever. By providing supportive relief when symptoms interfere with routine activities, it contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

---

Quick Facts: Symptomatic Relief Focus

• Key Symptom Focus: Joint Pain and Stiffness
• Benefit: Contributes to improved comfort during periods of heightened symptoms

Regulatory References

1. NIH MedlinePlus overview

Who Can and Cannot Use Метацин? (Indomethacin)

Official regulatory guidelines define strict eligibility criteria for the use of Метацин (Indomethacin).

Absolute Contraindications

Метацин is contraindicated and must not be used by patients with a known hypersensitivity or allergic reactions to NSAIDs (such as aspirin) or indomethacin itself. Use is also prohibited for the treatment of pain following coronary artery bypass graft (CABG) surgery. The medicine is strictly contraindicated in pregnancy from 30 weeks gestation onward. Other contraindications include active peptic ulceration and, for the suppository form, a history of proctitis or rectal bleeding.

Restricted and Conditional Use

Population/Condition	Eligibility Status
Pediatric Patients (<14 years)	Safety and effectiveness have not been established for oral/rectal forms.
Older Adults (ge 65 years)	Eligible, but requires close monitoring due to increased risk of adverse reactions.
Renal/Hepatic Impairment	Avoid use in advanced renal disease; use with caution and monitor function in milder impairment.
Pregnancy (20–30 weeks)	Restricted use; limited to the lowest effective dose for the shortest duration.

Eligibility is also contingent upon the absence of conditions like active bleeding, severe heart failure, or certain CNS disorders, which necessitate a cautious benefit-risk assessment by a healthcare professional.

Interactions with other medicines and products

Official regulatory documents classify interactions for Метацин (Indomethacin) based on specific constraints and required monitoring, primarily involving pharmacodynamic effects and altered drug clearance.

Prohibited and High-Risk Combinations

Co-administration with Diflunisal is prohibited due to the risk of severe gastrointestinal hemorrhage and a substantial increase in Метацин's plasma levels. The use of Метацин for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery is formally contraindicated. Concurrent use with analgesic doses of Aspirin or other NSAIDs is not recommended due to increased gastrointestinal risk.

Clinically Significant Monitoring Requirements

Interacting Agent	Official Interaction Profile
Anticoagulants (e.g., Warfarin)	Increased risk of bleeding and hemorrhage
Lithium	Метацин increases plasma Lithium levels and reduces clearance, requiring monitoring
Antihypertensives / Diuretics	May diminish the blood pressure-lowering or diuretic effect; risk of renal function deterioration in susceptible patients (e.g., elderly)
Digoxin	Метацин increases serum concentration and prolongs the half-life
Probenecid	May increase plasma levels of Метацин

Product and Population Notes

The label notes that Alcohol consumption and Smoking may increase the risk of gastrointestinal ulcers and bleeding. Patients who are elderly, volume-depleted, or have renal impairment require heightened monitoring for renal function when co-administering with ACE Inhibitors or ARBs.

How Метацин Works: Mechanism of Action

Метацин operates via M-cholinergic receptor antagonism, positioning itself as a non-selective antagonist on muscarinic acetylcholine ( M-ACh) receptors. This molecular interaction prevents the endogenous neurotransmitter acetylcholine from binding and activating the receptor, thereby interrupting the primary signal of the parasympathetic nervous system (PNS). This blockade results in a systemic reduction of parasympathetic tone.

The resulting mechanistic cascade in smooth muscle tissue, particularly in the gastrointestinal, biliary, and urinary tracts, involves the interruption of the ACh-mediated signal for contraction. This leads to an acute reduction in muscle tone and the physiological effect of spasmolysis (muscle relaxation), characterized by decreased peristaltic movement.

Concurrently, antagonism of M-receptors on exocrine glandular tissue suppresses the signaling sequence necessary for fluid output. This action yields an overall antisecretory effect, manifesting as inhibition of fluid release (e.g., reduced salivation and sweating). The drug's molecular properties ensure its action remains predominantly peripheral, with reduced effects on central nervous system targets.

How to Use Метацин (Indomethacin)

The administration of Метацин is defined by guidelines that specify the approved routes, dose, frequency, and conditions for proper use. The medicine is primarily available for oral intake as immediate-release capsules, extended-release capsules, and an oral suspension, as well as for rectal administration via suppositories. Intravenous (IV) use is reserved for specific, time-limited indications in controlled professional settings.

Standard Dosing and Schedule For managing chronic conditions, initial adult dosing typically starts at 25 mg two or three times a day (TID). The total daily dose may be gradually increased by 25 mg or 50 mg at weekly intervals, but should not exceed the official maximum of 200 mg per day. Acute conditions, such as gouty arthritis, require a higher fixed dose, usually 50 mg three times daily, which is continued for a short duration until the acute flare subsides.

Administration Conditions Oral capsules and suspension must be administered immediately after meals, with food, or with an antacid. This specific instruction is required to minimize potential gastrointestinal effects. Immediate-release capsules are taken in divided doses throughout the day, while extended-release capsules are typically taken once or twice daily. A key procedural restriction is that extended-release capsules must be swallowed whole and must not be crushed, opened, or chewed to maintain their controlled-release mechanism. Furthermore, a lower starting dose is frequently employed for older adults and patients with impaired renal or hepatic function.

Research Evidence / Overview of Studies for Метацин (Indomethacin)

The research base for Метацин (Indomethacin) includes Randomized Controlled Trials (RCTs) and scientific reviews. These studies, which follow rigorous standards, have been used in research exploring how symptoms change over time across several inflammatory conditions. This overview summarizes the structure of the available evidence as reported in peer-reviewed scientific literature.

Evidence for Managing Chronic Inflammatory Conditions

The core evidence structure includes studies that examined chronic inflammatory conditions, which are conditions characterized by fluctuating or episodic manifestations. These include rheumatoid arthritis (RA), osteoarthritis (OA), and ankylosing spondylitis (AS).

What researchers studied: Researchers conducted short-term and longer-term RCTs and comparative trials. These studies examined specific outcomes related to physical discomfort and functional well-being. For RA and OA, researchers typically monitored the number of tender or swollen joints and outcomes reflecting daily functioning or activity level, such as grip strength.

What remains uncertain: The research primarily evaluates symptomatic relief. The evidence structure does not characterize an impact on the long-term, structural progression of chronic diseases like RA or OA. Long-term studies focused on symptom control, and data are insufficient regarding evaluation of disease modification.

Research on Acute Symptomatic Control (Gout and Pain)

Research also evaluated Метацин's role in conditions associated with acute or disruptive episodes, such as acute gouty arthritis, a condition involving periods of heightened symptoms.

What researchers studied: For acute gout, the evidence base includes very short-term RCTs. These studies examined outcomes capturing phases of heightened symptom activity, such as the time needed to observe changes in pain, swelling, and redness. Comparative research was studied for the purpose of comparing the measured outcomes against other established treatments, including systemic corticosteroids.

What remains uncertain: For a single dose for general acute pain, the evidence is limited. Broad conclusions for various types of acute pain are still uncertain because sample sizes were modest and the studies apply only to the populations studied.

Key Studies & References

1. Indomethacin: MedlinePlus Drug Information
2. Indomethacin

Common questions about Метацин (FAQ)

Q: How long does it take for Метацин to start working?

Official product information, based on pharmacokinetic data (how the body processes the drug), indicates that the concentration of the active ingredient typically reaches its peak level in the bloodstream approximately two hours after a single dose. For acute conditions like gout, studies indicate that relief of pain has been reported within two to four hours.

Q: Can I drink a glass of wine while taking Метацин?

Regulatory documents note that the consumption of alcohol while using this medication is advised against. Regulatory warnings indicate that using this medicine with alcohol may elevate the risk of serious gastrointestinal side effects, such as internal bleeding.

Q: Can I take Метацин if I am on blood pressure medication?

Official labeling notes that this medicine may diminish the effect of certain blood pressure-lowering drugs, such as ACE inhibitors and diuretics. In patients taking these types of medications, close monitoring of blood pressure is required when starting or adjusting the dosage of this medicine.

Q: What should I do if I miss a dose of Метацин?

Official patient information often describes a standard procedure: if a dose is missed, it can be taken as soon as it is remembered. However, if the next scheduled dose is approaching, the label typically recommends skipping the missed dose and continuing with the regular schedule. Regulatory guidance advises against taking a double dose to compensate for a missed one.

Q: What is the difference between the capsule and the suppository?

While the suppository form may sometimes be used as an alternative to the oral capsule, regulatory data suggests there can be differences in how much medicine is absorbed into the bloodstream. Official product information contains a specific precaution: the suppository form is contraindicated (should not be used) in patients with a history of rectal bleeding or inflammation (proctitis).

Q: What is the half-life of Метацин?

According to the official prescribing information on pharmacokinetics, the average half-life (the time it takes for half of the drug to be eliminated from the body) is estimated to be approximately 4.5 hours.

Q: Is Метацин a muscle relaxer?

This medication is officially classified by regulatory bodies as a nonsteroidal anti-inflammatory drug (NSAID). While its mechanism of action includes relaxing smooth muscle tissue to help with spasms, it is not listed as a muscle relaxer in its approved indications and uses.

Official Storage and Disposal Instructions

Storage Component	Regulatory Requirement
Temperature	Store at controlled room temperature (20 C to 25 C or 68 F to 77 F). Excursions up to 30 C are permitted.
Environmental	Protect the medicine from excessive moisture and keep it in a tight container.
Child Safety	Mandatory instruction to keep out of the reach of children and out of their sight.
Disposal Method	Unused or expired product should be returned via a drug take-back program.
Water Disposal	Do not flush the medicine down the toilet or pour it into a drain unless explicitly instructed by the label.

Regulatory documents strictly mandate that the medicine must be protected from moisture and kept within the specified controlled room temperature to maintain product integrity. All containers must be stored securely and kept inaccessible to children. Disposal instructions prioritize collection programs, with a clear restriction against environmental disposal through wastewater systems.